Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 10/20 | 0.57 |
| ▸ | CTSD | P07339 | 9/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4121222 | 0.99 | BACE1 (0.59) | BACE1BACE2CTSDREN | |
| SCHEMBL4234023 | 0.88 | BACE1 (0.77) | BACE1BACE2CTSD | |
| SCHEMBL5069818 | 0.88 | BACE1 (0.77) | BACE1BACE2CTSD | |
| SCHEMBL4913709 | 0.86 | BACE1 (0.61) | BACE1BACE2CTSDREN | |
| SCHEMBL4913387 | 0.83 | BACE1 (0.59) | BACE1BACE2CTSDREN | |
| SCHEMBL4912053 | 0.82 | BACE1 (0.58) | BACE1BACE2CTSDREN | |
| SCHEMBL4782043 | 0.81 | BACE1 (0.57) | BACE1BACE2CTSDREN | |
| SCHEMBL7941295 | 0.80 | BACE1 (0.69) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL4115960 | 0.79 | BACE1 (0.68) | BACE1BACE2CTSD | |
| SCHEMBL4783919 | 0.79 | BACE1 (0.63) | BACE1BACE2CTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233943-A9 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | US | disclosed |
| US-20090233943-A9 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | US | disclosed |
| WO-2008150217-A1 | 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONE ANALOGS FOR THE INHIBITION OF BETA-SECRETASE | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080287460-A1 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287460-A1 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287460-A1 | NEW COMPOUNDS 835 | GRIK5, MAPT, PSEN1 | BACE1 6/4885BACE2 25/4885CTSD 1954/4885 |
| US-20090233943-A9 | NEW COMPOUNDS 835 | GRIK5, MAPT, PSEN1 | BACE1 6/4885BACE2 25/4885CTSD 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.